# A Study to Evaluate the Relative Bioavailability, Effect of Food, and Gastric Potential Hydrogen (pH) Modification on the Pharmacokinetics of TAK-117 (MLN1117) in Healthy Participants

> **NCT02625259** · PHASE1 · COMPLETED · sponsor: **Millennium Pharmaceuticals, Inc.** · enrollment: 54 (actual)

## Conditions studied

- Neoplasm, Advanced or Metastatic

## Interventions

- **DRUG:** TAK-117
- **DRUG:** Lansoprazole
- **DRUG:** TAK-117

## Key facts

- **NCT ID:** NCT02625259
- **Lead sponsor:** Millennium Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01-08
- **Primary completion:** 2016-05-16
- **Final completion:** 2016-07-22
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2018-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02625259

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02625259, "A Study to Evaluate the Relative Bioavailability, Effect of Food, and Gastric Potential Hydrogen (pH) Modification on the Pharmacokinetics of TAK-117 (MLN1117) in Healthy Participants". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT02625259. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*